Nasdaq Drops as AI Earnings, Oil Surge and Middle East Tensions Weigh on Wall Street 
Chalco Shares Jump as Chinalco Plans Up to $300 Million Stake Increase 
Asian Stocks Rally on AI Spending Optimism as Middle East Tensions Push Oil to Six-Week High 
Nvidia Reveals 9.3% Stake in AI Cloud Firm Nebius Following $2 Billion Investment 
US Stock Futures Rise as AI Optimism Lifts Tech, 3M Jumps on Strong Earnings 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
South Korea Q2 GDP Beats Forecasts as AI Chip Exports Drive Growth 
Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge 
US Stock Exchanges Face Earnings Test as Trading Boom Meets Crypto Competition 
ASEAN Ministers Warn Middle East Conflict Threatens Regional Stability and Energy Security 
Saudi Oil Tankers Reverse Course as Houthi Threats Disrupt Red Sea Shipping 
KPMG Australia Appoints John Sams as CEO Following Audit Leak Scandal 
Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad 
European Stocks Slip as Earnings, UK Inflation and ECB Decision Keep Investors on Edge 
Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
Trump Announces 100% Tariff on Generic Drug Imports Starting in 2028 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
